Anirban Maitra · @Aiims1742“Amazing news today, culmination of years of research & clinical trials in #PancreaticCancer. The @RevMedicines approval for Rasonque (Daraxonrasib) will open many doors, including other inhibitors in this space & combinations. @OncoAlert @KRASKickers”
View post ↗See the full RASolute 302 KOL reaction on KOL Pulse →A Phase II study of the investigational irreversible EGFR TKI sutetinib in NSCLC with uncommon EGFR mutations (G719X, S768I, L861Q, or compound) demonstrated a 70.8% overall response rate and 13.7 months median progression-free survival. Separately, a new study in Annals of Oncology found that thymus radiation exposure is associated with worse outcomes, including increased distant metastasis and reduced survival, in patients with NSCLC. The broader cancer vaccine landscape is also being discussed, with V940 and Tedopi noted as being in late-stage development for NSCLC.
“Phase II study of irreversible EGFR TKI sutetinib in NSCLC with uncommon EGFR mutations (G719X, S768I, L861Q, or compound) @JTOonline. RR 70.8%, DCR 90.6%, DOR 12m, PFS 13.7m. Most common G3+ TRAE was diarrhea (28%).”
— @StephenVLiu · Sutetinib in uncommon EGFRm NSCLC · View post ↗
“Thymus radiation exposure is linked to worse outcomes for cancer (non-small cell lung cancer) for distant metastasis and reduced survival”
— @EricTopol · Thymus radiation in NSCLC · View post ↗
“late-stage fields have only a few real lanes: V940 in melanoma/NSCLC, Tedopi in NSCLC, plus single-indication bets in prostate & breast”
— @mukundiyngr · Cancer vaccine landscape · View post ↗📌 Amplified by @KolPulseAI
Recent analyses of the CATALINA (TNBC) and APHINITY (HER2+) trials found that while Tumor-Infiltrating Lymphocytes (TILs) are prognostic, AI-based quantification does not add predictive value beyond standard clinicopathological features. A SEER database analysis of 2,260 patients with node-negative, non-metastatic (N0M0) metaplastic breast cancer identified older age, undifferentiated tumor, larger tumor size, and lack of chemo/radiotherapy as independent prognostic factors for worse survival.
“Same answer on counting: TILs are prognostic, but AI counting them faster adds nothing a pathologist and standard clinicopath don't already give you. Thermometer, not target...”
— @DrBarbiOnc · TILs as a biomarker · View post ↗
“Independent prognostic factor for worse breast cancer-specific or overall survival (Multivariable Cox model) ⬆️Age at diagnosis Undifferentiated tumor ⬆️Tumor size No Chemo/Radiotherapy”
— @HaoYin20 · Metaplastic Breast Cancer · View post ↗The FDA approved daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy — or for patients who are not candidates for multiagent systemic therapy — based on the RASolute 302 trial. GI oncologists led the reaction, highlighting overall survival of 13.2 vs 6.7 months (HR 0.4) vs chemotherapy, with a first-line Phase III ongoing. In colorectal cancer, the NEST trial of neoadjuvant botensilimab and balstilimab for MSS tumors showed 100% disease-free survival to date. Additionally, the EMERALD-3 trial in HCC showed efficacy for the STRIDE regimen with TACE, but noted the addition of lenvatinib was disappointing.
“Amazing news today, culmination of years of research & clinical trials in #PancreaticCancer. The @RevMedicines approval for Rasonque (Daraxonrasib) will open many doors, including other inhibitors in this space & combinations. @OncoAlert @KRASKickers”
— @Aiims1742 · Rasonque (daraxonrasib) approval · View post ↗
“Daraxonrasib now @US_FDA ✅ based off RASolute302: Daraxonrasib vs. Chemo in 2L metastatic pancreatic cancer: - ⬆️ OS: 13.2 vs. 6.7mos (HR: 0.4) - RAS mutation present in >90% pancreatic adenocarcinoma - One of the biggest advances/news in 2026 for cancer! #OncTwitter”
— @OncBrothers · RASolute 302 data · View post ↗
“Just to clarify: The current @FDA @Rev_Medicine indication is after >/= 1 prior line of therapy in #previously treated #pancreatic #cancer. There is an ongoing Phase III trial in the 1st -line setting for panc.”
— @CathyEngMD · Approved indication · View post ↗
“🆕👇🏽Unveiling FULL results of our #NEST🪺 Trial in MSS “cold”🧊colorectal cancer 💡Immunotherapy (BOT🤖/BAL) BEFORE surgery 💯% disease-free to date✅ NEST1:~32 months NEST2:~24 months 5 years of work—now in @CCR_AACR🙌🏽 🚀#NEST3 NOW OPEN! @OncoAlert 🔗”
— @pashtoonkasi · NEST trial · View post ↗
“STRIDE, with or without Lenva, combined with TACE in HCC: EMERALD-3 pts 3 study @LancetOncology https://t.co/3PE3B3mdz0 👉Interesting efficacy with STRIDE 👉Lenvatinib disappointing”
— @ArndtVogel · EMERALD-3 trial · View post ↗📌 Amplified by @KolPulseAI
“Pancreatic cancer surgery in Italy 🇮🇹outcomes by hospital volume 🏥 3.4k surgeries / 90day mortality 10% 🔴 <30 surg - mortality > 10% = 21% 🟡 30-50 surg - mortality >5% = 18% 🟢 >50 surg - mortality <5% = 61% 📣 Pancreas unit urgently needed 📣”
— @Gio_Marchegiani · Pancreatic surgery volume-outcomes · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Daiichi Sankyo and AstraZeneca have initiated a phase 3 trial of a DXd ADC combination for the adjuvant treatment of high-risk muscle-invasive urothelial cancer (MIUC). Separately, real-world data for enfortumab vedotin (EV) showed that 45.6% of patients were ineligible for the EV-301 trial and had worse outcomes, including an OS of 10.5 months versus 17.9 months for trial-eligible patients. Other discussions highlight a pooled analysis of two phase 2 trials evaluating metastasis-directed therapy with or without pembrolizumab for oligometastatic clear cell renal cell carcinoma.
“Almost half the patients we give EV to would never have made it into EV-301. While RWE may not be practice changing, but can give insights uptake, efficacy, AEs in non-trial patients.”
— @katy_beckermann · Enfortumab Vedotin RWE · View post ↗
“Resistance is not necessarily a property of the cancer cell alone. It can emerge from cooperation between tumor cells and their microenvironment.”
— @niklas_kluemper · MIBC Cisplatin Resistance · View post ↗
“Efficacy and patient-reported outcomes tell different stories — both matter for shared decision-making.”
— @drenriquegrande · QoL in Urothelial Cancer · View post ↗
“Novel perioperative strategies improve outcomes beyond GC in cisplatin-eligible MIBC”
— @crisbergerot · Perioperative MIBC Strategies · View post ↗New data in AL amyloidosis suggests the 1q21+ chromosomal abnormality is an inferior prognostic marker, particularly beyond 24 months, and is associated with a more 'myeloma-like' clone. The myeloma/hematology community is also discussing the biological basis of circulating plasma cells—whether their presence reflects true plasma cell leukemia biology or passive overflow from packed bone marrow—and the interpretation of oligoclonal bands post-treatment as a sign of immune recovery rather than relapse.
“Importantly piecewise Cox model shows that this inferior prognostic impact is mostly later in the disease course (beyond 24 months)”
— @ZanwarSaurabh · 1q21+ in AL Amyloidosis · View post ↗
“Are circulating plasma cells present because the malignant clone has acquired genuine biological features enabling it to leave the marrow and circulate/seed extramedullary sites (true PCL biology), or is peripheral blood involvement simply passive overflow from an extremely packed marrow (a mechanical/burden-driven phenomenon)?”
— @hhashmi87 · Circulating Plasma Cells · View post ↗
“A new band on immunofixation does not always indicate relapse. If it differs from the original myeloma protein, it may represent oligoclonal immune recovery after a deep treatment response.”
— @Abdallah81MD · Oligoclonal Bands · View post ↗
“The time has certainly come for T cell engaging control arms in 2L+ R/R myeloma”
— @Eddie_Cliff · Clinical Trial Design · View post ↗
“Immunoglobulin D-Associated AL Amyloidosis: Clinical Features and Outcomes - Clinical Lymphoma, Myeloma and Leukemia @BU_Amyloidosis”
— @vsanchorawala · IgD-associated AL amyloidosis · View post ↗A new publication in Blood Advances details the real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma. Another study from the DESCAR-T registry, published in Bone Marrow Transplant, examines response kinetics following CAR T-cell therapy for large B-cell lymphoma. Commentary also emphasized disparities in global access to standard-of-care therapies, citing imatinib for chronic myeloid leukemia as an example.
“My uncle had chronic myeloid leukemia when imatinib was already the standard but not available in Brazil's public health system. He died. Grandpa had access to another system and lived to ninety with a hundred of us in the room. Same family. Same country. Two endings, decided by access.”
— @GlopesMd · Global access to care · View post ↗